Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Metastatic Solid Tumors 1Mesothelioma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hemorrhage 1Hematologic Diseases 1Head and Neck Neoplasms 1Gynecological Solid Tumors 1Fallopian Tube Neoplasms 1Diarrhea 1Colitis 1Childhood Solid Tumor 1

Interventions

fludarabine 12Cyclophosphamide 11Busulfan 8Mycophenolic Acid 6Dexamethasone 6fludarabine phosphate 5Whole-Body Irradiation 5Tacrolimus 5Melphalan 5Lenalidomide 5Granulocyte Colony-Stimulating Factor 4isatuximab 3Thiotepa 3Sirolimus 3Rituximab 3Methotrexate 3Cyclosporine 3Blood Specimen Collection 3Alemtuzumab 3pomalidomide 2pembrolizumab 2daratumumab 2Vorinostat 2Stem Cell Transplantation 2Platelet Transfusion 2Ondansetron 2Interviews as Topic 2Filgrastim 2Exercise 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Diseases × Cell- and Tissue-Based Therapy × Clear all
NCT06849921 2025-02-27

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Ruijin Hospital

Phase NA Active not recruiting
200 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡